NCT03060694View on ClinicalTrials.gov

Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements

CompletedOBSERVATIONAL
Enrollment

58

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

May 31, 2017

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
OTHER

diabetes

"1. a history of diabetes and using anti-diabetic medicines.~2. fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."

Trial Locations (1)

Unknown

Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai

All Listed Sponsors
lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements | Biotech Hunter | Biotech Hunter